Steven Mah
Stock Analyst at TD Cowen
(2.22)
# 2,766
Out of 5,124 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $34.34 | +68.90% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $25.31 | +22.48% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $8.87 | +1,252.87% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.37 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $18.50 | +127.03% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.43 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.85 | +440.54% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.74 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $1.63 | +1,188.34% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $237.42 | -34.71% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $25.37 | +451.83% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.98 | +2,526.26% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $141.33 | +193.64% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $30.06 | +731.67% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $34.34
Upside: +68.90%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $25.31
Upside: +22.48%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $8.87
Upside: +1,252.87%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.37
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $18.50
Upside: +127.03%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.43
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.85
Upside: +440.54%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.74
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $1.63
Upside: +1,188.34%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $237.42
Upside: -34.71%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $25.37
Upside: +451.83%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.98
Upside: +2,526.26%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $141.33
Upside: +193.64%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $30.06
Upside: +731.67%